http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-20004146-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e19741e967ed6c909c17813b4f9ef63e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate | 1999-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b45947aaffb03ddac8b6ae26dd28ffda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f909a662f026416595c47d45fe67cc64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7755ddc1cc77ada41c12179f7e2656c9 |
| publicationDate | 2001-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-20004146-A3 |
| titleOfInvention | Binding molecules derived from immunoglobulins that do not trigger complement mediated lysis |
| abstract | Binding of recombinant polypeptide moleculesncomprising i) a binding region capable of binding the targetnand (ii) an effector region that exhibitsnan amino acid sequence substantially homologous to the entirenor a portion of the heavy chain constant region of a humannimmunoglobulin. The binding molecule is capable of binding the targetnmolecule without triggering a substantial ski dependentncomplement or cell-mediated target damage.nIt is preferred that the effector region be capable of specificitynbind FcRn and / or FcγRIIb. These binding molecules arengenerally based on chimeric regions that have been derived fromntwo or more Ch 2 heavy chain regions of humannimmunoblogulin. In a preferred embodiment, the regions 233 ton236 and 327-331 have been modified to impart a moleculenzero allotype. Host cell nucleic acids, methodsnproduction, materials and uses. Pharmaceutical compositions withnthe content of these compounds and their use for treatmentnautoimmune, alloimmune and inflammatory diseases. |
| priorityDate | 1999-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.